{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:41Z","timestamp":1790770121934,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,7]],"date-time":"2012-10-07T00:00:00Z","timestamp":1349568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1472-6874-12-35","type":"journal-article","created":{"date-parts":[[2012,10,7]],"date-time":"2012-10-07T00:14:48Z","timestamp":1349568888000},"source":"Crossref","is-referenced-by-count":24,"title":["Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology"],"prefix":"10.1186","volume":"12","author":[{"given":"Ghizlane","family":"Rais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soundouss","family":"Raissouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Aitelhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadoi","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Naciri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Khoyaali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Abahssain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bensouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Khannoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Mrabti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Errihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,7]]},"reference":[{"key":"296_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"S Rebecca","year":"2011","unstructured":"Rebecca S, Elizabeth W, Otis B, Ahmedin J: Cancer Statistics, 2011 CA. Cancer J Clin. 2011, 61: 212-236. 10.3322\/caac.20121.","journal-title":"Cancer J Clin"},{"key":"296_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature. 2000, 406: 747-752. 10.1038\/35021093.","journal-title":"Nature"},{"key":"296_CR3","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibsirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073\/pnas.191367098.","journal-title":"Proc Natl Acad Sci USA"},{"key":"296_CR4","doi-asserted-by":"publisher","first-page":"9212","DOI":"10.1073\/pnas.96.16.9212","volume":"96","author":"CM Perou","year":"1999","unstructured":"Perou CM, Jeffrey SS, Van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999, 96: 9212-9217. 10.1073\/pnas.96.16.9212.","journal-title":"Proc Natl Acad Sci USA"},{"key":"296_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/156652412798376134","volume":"12","author":"F Bertucci","year":"2012","unstructured":"Bertucci F, Finetti P, Birnbaum D: Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012, 12: 96-110. 10.2174\/156652412798376134.","journal-title":"Curr Mol Med"},{"key":"296_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006, 295: 2492-2502. 10.1001\/jama.295.21.2492.","journal-title":"JAMA"},{"key":"296_CR7","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13: 4429-4434. 10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/cncr.25862","volume":"117","author":"KC Amirikia","year":"2011","unstructured":"Amirikia KC, Paul M, Jason B, Newman LA: Higher population-based incidence rates of triple-negative breast cancer among young african-american women. Cancer. 2011, 117: 2747-2753. 10.1002\/cncr.25862.","journal-title":"Cancer"},{"key":"296_CR9","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1002\/cncr.25961","volume":"117","author":"L-M Fernando","year":"2011","unstructured":"Fernando L-M, et al: Triple-negative breast cancer in hispanic patients high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011, 117: 3658-3669. 10.1002\/cncr.25961.","journal-title":"Cancer"},{"key":"296_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.22836","volume":"110","author":"GJ Morris","year":"2007","unstructured":"Morris GJ, Naidu S, Topham AK, et al: Differences in breast carcinoma characteristics in newly diagnosed African- American and caucasian patients. Cancer. 2007, 110: 876-884. 10.1002\/cncr.22836.","journal-title":"Cancer"},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1158\/0008-5472.CAN-06-1927","volume":"66","author":"K Amend","year":"2006","unstructured":"Amend K, Hicks D, Ambrosone C: Breast cancer in African- American women: differences in tumor biology from European- American women. Cancer Res. 2006, 66: 8327-8330. 10.1158\/0008-5472.CAN-06-1927.","journal-title":"Cancer Res"},{"key":"296_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jnci\/djj223","volume":"98","author":"A Whitworth","year":"2006","unstructured":"Whitworth A: New research suggests access, genetic differences play role in high minority cancer death rate. J Natl Cancer Inst. 2006, 98: 669-10.1093\/jnci\/djj223.","journal-title":"J Natl Cancer Inst"},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/1756-0500-4-500","volume":"4","author":"Y Akasbi","year":"2011","unstructured":"Akasbi Y, Sanae B, Fouad A, Kawtar Z, Joutei KA, Afaf A, Omar EL M: Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Research Notes. 2011, 4: 500-10.1186\/1756-0500-4-500.","journal-title":"BMC Research Notes"},{"key":"296_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","volume":"16","author":"B Chevallier","year":"1993","unstructured":"Chevallier B, Roche H, Olivier JP, et al: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993, 16: 223-228. 10.1097\/00000421-199306000-00006.","journal-title":"Am J Clin Oncol"},{"key":"296_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10552-009-9331-1","volume":"20","author":"KF Trivers","year":"2009","unstructured":"Trivers KF, Mary Jo L, Porter PL, Liff JM, Flagg EW, Coates RJ, William Eley J: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009, 20: 1071-1108. 10.1007\/s10552-009-9331-1.","journal-title":"Cancer Causes Control"},{"key":"296_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jnci\/87.11.827","volume":"87","author":"LA Brinton","year":"1995","unstructured":"Brinton LA, Daling JR, Liff JM, et al: Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995, 87: 827-835. 10.1093\/jnci\/87.11.827.","journal-title":"J Natl Cancer Inst"},{"key":"296_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-08-1005","volume":"18","author":"JM Dolle","year":"2009","unstructured":"Dolle JM, Daling JR, White E, et al: Risk factors for triplenegative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009, 18: 1157-1166. 10.1158\/1055-9965.EPI-08-1005.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1158\/0008-5472.CAN-06-3895","volume":"67","author":"PB Gupta","year":"2007","unstructured":"Gupta PB, Proia D, Cingoz O, et al: Systemic stromal effects of estrogen promote the growth of estrogen receptornegative cancers. Cancer Res. 2007, 67: 2062-2071. 10.1158\/0008-5472.CAN-06-3895.","journal-title":"Cancer Res"},{"key":"296_CR19","doi-asserted-by":"publisher","first-page":"8010","DOI":"10.1158\/1078-0432.CCR-08-1208","volume":"14","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14: 8010-8018. 10.1158\/1078-0432.CCR-08-1208.","journal-title":"Clin Cancer Res"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al: Incidence and outcome of BRCA mutations inunselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011, 17: 1082-1089. 10.1158\/1078-0432.CCR-10-2560.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"296_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1586\/era.09.189","volume":"10","author":"R Venkitaraman","year":"2010","unstructured":"Venkitaraman R: Triple-negative\/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther. 2010, 10 (2): 199-207. 10.1586\/era.09.189.","journal-title":"Expert Rev Anticancer Ther"},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-10-0939","volume":"16","author":"CK Anders","year":"2010","unstructured":"Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, et al: Poly (ADP-ribose) polymerase inhibition: targeted therapy for triple negative breast cancer. Clin Cancer Res. 2010, 16: 4702-4710. 10.1158\/1078-0432.CCR-10-0939.","journal-title":"Clin Cancer Res"},{"key":"296_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al: Inhibition of poly(ADP-ribose) polymerase intumors from BRCA mutation carriers. N Engl J Med. 2009, 361: 123-134. 10.1056\/NEJMoa0900212.","journal-title":"N Engl J Med"},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","volume":"20","author":"O Gluz","year":"2009","unstructured":"Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N: Triple negative breast cancer\u2013current status and future directions. Ann Oncol. 2009, 20: 1913-1927. 10.1093\/annonc\/mdp492.","journal-title":"Ann Oncol"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 2007, 109: 25-32. 10.1002\/cncr.22381.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"296_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0959-8049(09)70013-9","volume":"45","author":"SJ Dawson","year":"2009","unstructured":"Dawson SJ, Provenzano E, Caldas C: Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009, 45 (Suppl 1): 27-40.","journal-title":"Eur J Cancer"},{"key":"296_CR27","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006, 24: 5652-5657. 10.1200\/JCO.2006.06.5664.","journal-title":"J Clin Oncol"},{"key":"296_CR28","doi-asserted-by":"crossref","unstructured":"Cornelia L, Chafika M, Hess KR, Fabrice A\u2019, Attila T, Mejia JA, Fraser Symmans W, Gonzalez-Angulo AM, Bryan H, Marjorie G, Massimo C, Hortobagyi GN, Lajos P: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26: 1275-1281.","DOI":"10.1200\/JCO.2007.14.4147"},{"issue":"4","key":"296_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/156800909788486722","volume":"9","author":"F Bellati","year":"2009","unstructured":"Bellati F, Visconti V, Napoletano C, Antonilli M, Frati L, Panici PB, Nuti M: Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets. 2009, 9 (4): 541-565. 10.2174\/156800909788486722.","journal-title":"Curr Cancer Drug Targets"},{"key":"296_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010, 28: 105-113. 10.1200\/JCO.2009.23.7370.","journal-title":"J Clin Oncol"},{"issue":"27","key":"296_CR31","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1200\/JCO.2010.27.9984","volume":"28","author":"F Bellati","year":"2010","unstructured":"Bellati F, Napoletano C, Gasparri M, Benedetti Panici P, Nuti M: Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm. J Clin Oncol. 2010, 28 (27): e471-e472. 10.1200\/JCO.2010.27.9984.","journal-title":"J Clin Oncol"},{"key":"296_CR32","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056\/NEJMoa072113.","journal-title":"N Engl J Med"},{"key":"296_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, German Breast Group and the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie\u2013Breast Study Groups, et al: Neoadjuvant chemotherapy and bevacizumab for HER2-Negative Breast. Cancer N Engl J Med. 2012, 366: 299-309. 10.1056\/NEJMoa1111065.","journal-title":"Cancer N Engl J Med"},{"key":"296_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-9966-30-54","volume":"30","author":"C Federica","year":"2011","unstructured":"Federica C, et al: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011, 30: 54-10.1186\/1756-9966-30-54.","journal-title":"J Exp Clin Cancer Res"},{"key":"296_CR35","volume-title":"Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer","author":"A Tutt","year":"2009","unstructured":"Tutt A, Robson M, Garber JE, et al: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol. 2009, 27 (18 suppl): Abstract CRA501"},{"key":"296_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJMp1012997","volume":"364","author":"J O\u2019Shaughnessy","year":"2011","unstructured":"O\u2019Shaughnessy J, Osborne C, Pippen J, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011, 364: 3-10.1056\/NEJMp1012997.","journal-title":"N Engl J Med"},{"key":"296_CR37","doi-asserted-by":"publisher","first-page":"81s","DOI":"10.1200\/JCO.2010.31.5317","volume":"29","author":"J O'Shaughnessy","year":"2011","unstructured":"O'Shaughnessy J, Schwartzberg LS, Danso MA, et al: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine\/carboplatin (G\/C) in metastatic triple-negative breast cancer (TNBC) (abstract 1007). J Clin Oncol. 2011, 29: 81s-10.1200\/JCO.2010.31.5317. Abstract available online at http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78038 (Accessed on July 08, 2011)","journal-title":"J Clin Oncol"},{"key":"296_CR38","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","volume":"30","author":"LA Carey","year":"2012","unstructured":"Carey LA, Rugo HS, Marcom PK, et al: TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. J Clin Oncol. 2012, 30: 2615-10.1200\/JCO.2010.34.5579.","journal-title":"J Clin Oncol"},{"key":"296_CR39","volume-title":"Preliminary results of a randomized phase II study of weekly irinotecan\/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstract 308]","author":"J O\u2019Shaughnessy","year":"2007","unstructured":"O\u2019Shaughnessy J, Weckstein DJ, Vukeelja SJ, et al: Preliminary results of a randomized phase II study of weekly irinotecan\/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstract 308]. 2007, San Antonio Breast Cancer Symposium, San Antonio, Texas"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-12-35\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-12-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-12-35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-12-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T13:09:01Z","timestamp":1562245741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-12-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-12-35","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,7]]},"article-number":"35"}}